Synlogic (NASDAQ:SYBX – Get Free Report) and Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Profitability
This table compares Synlogic and Allarity Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synlogic | N/A | -26.47% | -18.00% |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
Earnings and Valuation
This table compares Synlogic and Allarity Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synlogic | $8,000.00 | 1,684.24 | -$23.36 million | ($0.06) | -18.33 |
| Allarity Therapeutics | $320,000.00 | 49.22 | -$11.23 million | ($0.78) | -1.27 |
Allarity Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Synlogic and Allarity Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synlogic | 0 | 0 | 0 | 0 | 0.00 |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 935.35%. Given Allarity Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Synlogic.
Volatility and Risk
Synlogic has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Insider and Institutional Ownership
63.4% of Synlogic shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Synlogic beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
